The field of medicinal chemistry is constantly seeking novel molecular structures with therapeutic potential, and quinazoline derivatives have emerged as a particularly fruitful area of research. These heterocyclic compounds form the core of many important drugs, including several targeted cancer therapies. N-(3-Chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine (CAS 162012-67-1) is a significant example, serving as a key intermediate in the synthesis of Afatinib.

The quinazoline ring system itself is a fused bicyclic structure containing two nitrogen atoms. Modifications to this core structure, such as the addition of specific functional groups and substituents, can dramatically alter its biological activity. In the case of N-(3-Chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine, the presence of a chloro-fluorophenyl group and a nitro group on the quinazoline ring contributes to its specific reactivity and utility in subsequent synthetic steps. The meticulous N-(3-chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine synthesis is crucial for generating this precise structure.

The role of this compound as an Afatinib intermediate A highlights the importance of intermediates in the pharmaceutical supply chain. The Afatinib intermediate uses are well-established, leveraging the reactive sites on the quinazolinamine structure to build the final drug molecule. The efficiency and success of these transformations depend heavily on the purity and quality of the starting intermediate, making the selection of a reliable CAS 162012-67-1 supplier a critical decision for drug manufacturers.

Beyond its direct application in Afatinib synthesis, the study of quinazolinamine derivatives is an active area of oncology drug development. Researchers are investigating these compounds for their potential activity against a range of cancers by targeting various molecular pathways. The structural versatility of the quinazoline scaffold allows for the design of new molecules with improved potency, selectivity, and pharmacokinetic profiles. Therefore, understanding the synthesis and properties of intermediates like N-(3-Chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine contributes to the broader advancement of medicinal chemistry.

NINGBO INNO PHARMCHEM CO.,LTD., as a provider of high-quality pharmaceutical intermediates, plays a vital role in supporting these research and development efforts. By ensuring the availability of compounds like N-(3-Chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine, they facilitate the progress of drug discovery pipelines. The Afatinib intermediate A price and its accessibility directly impact the pace at which new treatments can be brought to market.

In summary, quinazolinamine derivatives represent a significant class of compounds in medicinal chemistry, with N-(3-Chloro-4-fluorophenyl)-7-fluoro-6-nitroquinazolin-4-amine standing out due to its role in Afatinib production. Their complex synthesis and precise application underscore the depth of chemical expertise required in the pharmaceutical industry.